Abstract
Gastroesophageal reflux disease (GERD) is a recognized potential adverse event following peroral endoscopic myotomy (POEM). Proton pump inhibitors (PPIs) are an effective first-line therapy for GERD; although their efficacy can be affected by genotype cytochrome P450 2C19 (CYP2C19) variability. CYP2C19 rapid (RM) or intermediate metabolizer (IM) genotype may be associated with refractoriness to PPI therapy.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
